TrialAlimentary pharmacology & therapeutics2026

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).

Marco Sanduzzi-Zamparelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.